Please login to the form below

Not currently logged in
Email:
Password:

antibody drug conjugate

This page shows the latest antibody drug conjugate news and features for those working in and with pharma, biotech and healthcare.

BCMA in the spotlight as ASH abstracts drop

BCMA in the spotlight as ASH abstracts drop

Also up for presentation is GlaxoSmithKline’s anti-BCMA antibody-drug conjugate (ADC) GSK2857916 and bispecific antibodies from Amgen (AMG 420) and Pfizer (PF-06863135). ... Among the drug candidates, Amgen’s 35-patient study of AMG 420 revealed an

Latest news

  • Roche preps new Kadcyla filings after phase 3 trial win Roche preps new Kadcyla filings after phase 3 trial win

    Roche preps new Kadcyla filings after phase 3 trial win. Says the drug significantly reduced IDFS in women with residual disease. ... Now, Roche has clinical data showing its antibody-drug conjugate Kadcyla offers a second-line of treatment for these

  • Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3 Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

    Daiichi-Sankyo has ambitions to carve out a slice of the HER2 inhibitor market, and is pitting its antibody drug conjugate (ADC) against one of the incumbents – Roche’s Kadcyla – in ... If successful in phase 3, Daiichi-Sankyo’s drug could muscle

  • Boehringer’s Corsico to be new GSK drug dev leader Boehringer’s Corsico to be new GSK drug dev leader

    headhunted from his role at Google-owned drug research division Calico a year ago. ... data. The company’s most advanced oncology assets are both in phase 2: a BCMA targeting antibody drug conjugate and a TCR T-cell immunotherapy being developed with

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    AZ nabs US approval for new leukaemia drug Lumoxiti. Adds to firm's growing oncology franchise. ... regulator. The CD22-directed antibody-drug conjugate (ADC) – which seeks out an destroys cells bearing the CD22 transmembrane protein – is one of the

  • Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE

    Expected launches in this period include two new dual therapy treatments for HIV, dolutegravir lamivudine and cabotegravir ripilvirine, and GSK’s most advanced new oncology treatment, 2857916 (BCMA antibody-drug conjugate), ... The UK list price of the

More from news
Approximately 2 fully matching, plus 60 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    used to progress the clinical development of the company's immuno-oncology antibody therapeutics against the checkpoint targets CTLA-4 and PD-1. ... Also in January Immunomedics sold tiered royalty rights on global net sales of its antibody drug conjugate

  • Pharma deals continue to slide Pharma deals continue to slide

    Roche has licensed a monoclonal antibody in phase II to Dermira, a dermatology company. ... 250+. Immunogen (US). Jazz (IE, US). Collaboration and option. Phase I haematology-related antibody-drug conjugate plus 2 other projects.

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.

  • Deal Watch April 2016 Deal Watch April 2016

    Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3. ... Phase I antibody drug conjugate targeting cancer stem cell protein DLL3.

  • Deal Watch January 2016 Deal Watch January 2016

    363. Complix/ Merck &Co. Collaboration. Drug discovery collaboration to develop Cell-Penetrating Alphabodies (CPABs) for the treatment of cancer. ... Abzena/(Partner nd). Licence . Novel site specific ThioBridge antibody drug conjugate (ADC) linker

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    Antibody drug conjugate development company, Glythera has appointed Dr Mike Owen as its non-executive director. ... At GSK, Owen was responsible for initiating and growing the group’s pre-clinical and clinical therapeutic antibody pipeline through

  • ADC Therapeutics expands team ADC Therapeutics expands team

    ADC Therapeutics expands team. Appointments preceed its first antibody drug conjugate trials. ... ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics